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A B S T R A C T
We recently established a mouse model (288–330+/+) that developed acute respiratory disease resembling
human pathology following infection with a high dose (5 × 106 PFU) of mouse-adapted MERS-CoV
(icMERSma1). Although this high dose conferred fatal respiratory disease in mice, achieving similar pathology at
lower viral doses may more closely reflect naturally acquired infections. Through continued adaptive evolution
of icMERSma1 we generated a novel mouse-adapted MERS-CoV (maM35c4) capable of achieving severe re-
spiratory disease at doses between 103 and 105 PFU. Novel mutations were identified in the maM35c4 genome
that may be responsible for eliciting etiologies of acute respiratory distress syndrome at 10–1000 fold lower viral
doses. Importantly, comparative genetics of the two mouse-adapted MERS strains allowed us to identify specific
mutations that remained fixed through an additional 20 cycles of adaptive evolution. Our data indicate that the
extent of MERS-CoV adaptation determines the minimal infectious dose required to achieve severe respiratory
disease.
1. Introduction
Middle East respiratory syndrome is an emerging viral respiratory
infection caused by Middle East respiratory syndrome coronavirus
(MERS-CoV), first identified in Saudi Arabia in 2012. This novel cor-
onavirus is associated with severe pneumonia and acute respiratory
distress syndrome (ARDS) that often results in mortality (~ 35%)
(Alsaad et al., 2017; Arabi et al., 2017; Ng et al., 2016). Over 2100 cases
and 733 deaths have been reported in twenty-seven countries through
December 2017, all geographically linked to the Middle East (WHO,
2017). Though sporadic infections and small nosocomial outbreaks
continue to occur across the Arabian Peninsula, the potential for global
transmission was demonstrated by an outbreak in South Korea in 2015
(Arabi et al., 2017). Spread from a single infected individual returning
from the Arabian Peninsula resulted in 186 confirmed cases with a ~
20% mortality rate (Lee, 2015). Current treatment for MERS-CoV relies
on supportive treatment of symptoms, with potential MERS-CoV ther-
apeutic countermeasures gradually progressing toward clinical trials.
Developing therapeutic strategies has been hindered by a poor un-
derstanding of viral pathogenesis in humans, which has created chal-
lenges in developing applicable animal models that resemble the
human disease outcomes. Only recently have there been two case re-
ports describing the pathological consequences observed in MERS-CoV
infected patients (Alsaad et al., 2017; Ng et al., 2016). Non-human
primates (NHPs) offer advantages in preclinical therapeutic testing due
to their physiological similarities to humans. Two NHP models (rhesus
macaques and marmosets) were shown to support MERS-CoV infection;
however, there are limitations with regard to the ability to detect re-
plicating MERS-CoV in the lungs and the extent of respiratory disease
appears to vary from mild-to-severe in a laboratory dependent manner
(Chan et al., 2015; Falzarano et al., 2014; Johnson et al., 2016, 2015;
Munster et al., 2013). Importantly, this may be a consequence of dif-
ficulty in establishing MERS-CoV infection in the lower respiratory
tract, where the dipeptidyl peptidase 4 (DPP4) receptor is pre-
dominantly expressed in the human respiratory tract (Meyerholz et al.,
2016), or potential species-specific differences in DPP4 signaling me-
chanisms may impact production of high titer MERS-CoV. Complexities
in establishing infection in NHPs suggest that MERS-CoV may not be
adapted to elicit the severe respiratory disease often associated with
human infections. MERS-CoV adaptation by repeated passage within
these NHP species may help to enhance virulence and replicate severe
human disease reliably in NHPs.
Species adaptation has shown to be previously successful in estab-
lishing MERS-CoV infection that elicited lethal respiratory disease in
two humanized mouse models (Cockrell et al., 2016; Li et al., 2017a).




data indicate that novel virus genetic mutations were acquired during
additional rounds of adaptation in the 288–330+/- mice. To gain insight
into these genetic changes plaque purification was used to isolate a
novel clone from the more virulent maMERS-35.
2.2. A clonal isolate of maMERS-35 induces fatal respiratory disease in
288–330+/+ mice
A clonal isolate (maM35c4) was derived from a plaque purified
virus of maMERS-35 on CCL81 Vero cells. 288–330+/+ mice were in-
tranasally infected with three different doses of maM35c4 (5 × 103, 5
× 104, and 5 × 105 PFU) (Fig. 2). Severe weight loss (> 20%) was
associated with 5 × 104 and 5 × 105 PFU by day 7 p.i., with little
weight loss at the 5 × 103 PFU dose (Fig. 2a). Significant mortality
(50% succumbed to disease during the course of the experiment) was
observed at the 5 × 105 PFU dose, whereas all animals survived
through day 7 p.i. at the 5 × 104 and 5 × 103 PFU doses (Fig. 2b).
Graphing survival at 20% or 30% weight loss demonstrates decreased
survival at 5 × 103 and 5 × 104 PFU doses (Supplementary Fig. 1).
However, all mice were euthanized as mice receiving 5 × 104 and 5 ×
105 PFU doses approached our 30% weight exclusion limit. Based on
these results we would suggest an LD50 of ~ 1–2 × 104 PFU. Dramatic
weight loss and mortality correlated well with severe respiratory dis-
ease as quantified by gross investigation of hemorrhaging in the lungs
at days 3 and 7 post-infection (Fig. 2c). Lungs were scored for hemor-
rhaging on a scale of 0 (no hemorrhaging) to 4 (severe hemorrhaging)
throughout all lung lobes. Early after infection (day 3 p.i.), hemorrhage
scores correlated with the dose of virus administered (Fig. 2c). Com-
pared to minor hemorrhaging at 5 × 103 PFU, both the 5 × 104 and 5
× 105 infectious doses elicited significant hemorrhaging at day 3 p.i.
(Fig. 2c). By day 7 p.i. 5 × 104 and 5 × 105 PFU doses invoked dra-
matic hemorrhaging across all lung lobes (Fig. 2c). Interestingly, al-
though minimal weight loss occurred in mice infected with 5 × 103
PFU dose, substantial lung hemorrhaging was observed by day 7 p.i.,
indicating that the 5 × 103 dose of maM35c4 causes significant lung
disease (Fig. 2c). The viral loads in the lungs are consistent with the
disease elicited by the different doses (Fig. 2d). At day 3 p.i. ma-
MERS35c4 replicated to high titers (108–109 PFU/ml/gram lung tissue)
in the lungs at all doses, with mean lung titers increasing with increased
dose (Fig. 2d). Titers at day 7 p.i. exhibited a dose-dependent effect on
clearance of maM35c4 from the lungs (Fig. 2d). Mice infected with 5 ×
103 PFU dose show little to no detection of virus at day 7 p.i., while
higher titers persist in mice infected at both 5 × 104 and 5 × 105 PFU
doses (Fig. 2d). Weight loss, mortality, hemorrhaging and viral load in
the lungs are consistent with a dose-dependent effect on MERS-CoV-
induced disease. Lung disease by gross hemorrhaging was observed at
doses as low as 5 × 103 PFU, indicating that infection elicited dramatic
pathological changes in the lung architecture.
2.3. maM35c4 causes widespread infection of the lungs and pathology
characteristic of acute respiratory distress syndrome (ARDS)
MERS-CoV viral loads in the lungs of infected humans exhibit a
phased correlation with the development of respiratory disease. Viral
loads peak early after infection and as viral loads begin to decrease,
symptoms associated with respiratory disease increase (Oh et al., 2016).
A similar correlation was observed following infection of 288–330+/+
mice with maM35c4. Mouse-adapted M35c4 reached peak viral loads
shortly after infection (3 days p.i.), and began to resolve at late times
post-infection (7 days p.i.) (Fig. 2d and Fig. 3). MERS-CoV nucleocapsid
antigen staining by immunohistochemistry revealed widespread infec-
tion of the lungs at day 3 p.i. at all three doses and substantial clearance
by day 7.p.i., affecting both the parenchyma and airway epithelium
(Fig. 3 and Table 1). This corresponds well with the dose-dependent
effect of viral loads in the lungs (Fig. 2d). Consistent with viral re-
plication peaking early by day 3 p.i. the initial signs of lung pathology
short palindromic repeats and CRISPR-associated gene 9) technology to 
make amino acid substitutions at positions 288 and 330 of mDPP4 to 
generate a humanized mouse model (288–330 +/+) that supported 
high levels of virus replication. Fifteen serial passages of virus in het-
erozygous 288–330+/- mice resulted in a mouse-adapted virus (ic-
MERSma1) capable of achieving dramatic weight loss, severe lung pa-
thology, and lethal respiratory disease in 288–330+/+ mice. 
Importantly, minimizing changes to the mDPP4 precluded disruption of 
its innate role in glucose homeostasis and immune dysregulation 
(Ohnuma et al., 2008; Rohrborn et al., 2015). By replicating clinical 
disease, while also preserving host-specific DPP4 expression patterns 
and immune functionality, this humanized mouse model offers a useful 
tool to study pathogenesis and therapeutic testing.
A limitation of the icMERSma1 virus was the high dose (5 × 106 
PFU) required to produce severe respiratory disease through the in-
tranasal route of infection (Cockrell et al., 2016); whereas, other MERS-
CoV mouse models demonstrated that disease could be achieved at 
lower infectious doses (Coleman et al., 2017; Li et al., 2017a). Evidence 
in MERS-CoV infected patients indicates that there may be an associa-
tion between virus dose and the severity of respiratory disease (Oh 
et al., 2016). Initiating disease through natural acquisition of MERS-
CoV may also be dose dependent. Therefore, to achieve a dose that 
more closely resembles a naturally acquired infection we continued the 
adaptive evolution of icMERSma1 in 288–330+/- mice. We generated a 
novel mouse-adapted MERS-CoV clone (maM35c4) that confers pa-
thology indicative of severe respiratory disease at substantially lower 
doses in 288–330+/+ mice. Mouse-adapted M35c4 causes pathology 
similar to icMERSma1, but exhibited dose-dependent effects at 103–105 
PFU. We identified unique mutations in the maM35c4 clone that may 
promote severe respiratory disease at 10–1000 fold lower virus doses 
than previously observed. Most notably, comparative genetics of 
maM35c4 and icMERSma1 provided us a distinct advantage by al-
lowing us to identify mutations that remained fixed after an additional 
20 passages, implicating their importance in conferring virulence in 
mice.
2. Results
2.1. Evolving MERS-CoV in mouse lung maintains disease at lower 
infectious doses
MERS-CoV was mouse-adapted by serial passage through the lungs 
of the heterozygous, 288–330+/- mice as previously described (Cockrell 
et al., 2016). Fatal disease was routinely observed at the 5 × 106 PFU 
dose (Cockrell et al., 2016), a potential limitation that could be over-
come through continued passaging through the lungs of 288–330+/-
mice (Cockrell et al., 2016). Here, we demonstrate that continued 
passaging of the icMERSma1 virus through the lungs of 288–330+/-
mice yielded mouse-adapted MERS strains that exhibited dramatic 
weight loss after 25 and 35 passages, respectively referred to as ma-
MERS-25 and maMERS-35. The two heterogeneous mouse-adapted 
MERS-CoV populations (maMERS-25 and maMERS-35) were expanded 
in CCL81 Vero cells and tested at 5 × 104 and 5 × 105 PFU doses by 
intranasal inoculation of the 288–330+/+ mice (Fig. 1). Significant 
weight loss was observed through day 8 post-infection (p.i.) at two 
different doses. Mouse-adapted maMERS-35 exhibited the most sig-
nificant weight loss at both 5 × 104 PFU and 5 × 105 PFU with average 
weight loss of > 20% at both doses (Figs. 1a and 1b). Notably, all mice 
were euthanized as they approached our 30% weight exclusion limit. 
We anticipate that these mice would have succumbed to disease at later 
times post-infection. In contrast, the mice infected with maMERS-25 
only reached 16–22% weight loss (Figs. 1a and 1b), indicating that 
maMERS-25 may be less virulent than maMERS-35. Despite the dif-
ferences in disease severity, increased passaging resulted in two novel 
MERS-CoV heterogeneous virus populations that elicit weight loss, 
which is commonly associated with severe respiratory disease. These
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Fig. 1. MERS-35 elicits enhanced disease at decreased viral doses. a. Mouse weights were measured daily up to day 8 p.i. for 288–330+/+ mice infected intranasally with 5 × 105
PFU MERS-25 (n=3, blue circles) or MERS-35 (n= 3, red triangles). b. Mouse weights were measured daily up to day 8 p.i. for 288–330+/+ mice infected intranasally with 5 × 104 PFU
MERS-25 (n = 3) or MERS-35 (n = 3). All data are daily means of the percent weight relative to day 0± S.E.M.
Fig. 2. Mouse-adapted M35c4 exhibits significant respiratory disease at low infectious doses. Mice were infected intranasally with 5 × 103 (n = 13, black triangles), 5 × 104 (n =
12, blue squares), or 5 × 105 (n= 12, red circles) PFU of maM35c4. Mice were monitored daily for weight loss (a) and survival (b). The severity of hemorrhage was scored on a scale of 0
(no hemorrhage) to 4 (complete hemorrhage) (c), and lung titers were measured (d), for 288–330+/+ mice infected with the 5 × 103 dose at day 3 p.i. (n= 4) and day 7 p.i. (n= 9), 5 ×
104 dose at day 3 p.i. (n = 4) and day 7 p.i. (n = 8), and 5 × 105 dose at day 3 p.i. (n = 4) and day 7 p.i. (n = 4). All data are represented as means± S.E.M. For lung titers below the
limit of detection values were set at 1 to depict those mice on the graph.
were observed by day 3 p.i. (Table 1), with ARDS-related pathological
changes most prevalent at day 7 p.i. (Fig. 4 and Table 1). Changes in
lung architecture were most dramatic in mice infected with 5 × 105
PFU (Fig. 4a-d). Quantitative assessment of hyaline membrane forma-
tion exhibits a clear dose related phenotype, with most dramatic disease
exhibited at the 5 × 105 PFU dose (Table 1). A low magnification image
of a large airway showed denuding of the epithelial cell layer when
viewed from left-to-right, debris in the airway, severe polynuclear in-
filtration in the alveoli and alveoli ducts, and hyaline membrane for-
mation, reflecting many of the exhibited pathologies noted in human
cases with severe acute respiratory distress syndrome (Fig. 4a-d). Al-
though hyaline membrane formation was less frequent in mice at the 5
× 104 PFU dose, severe inflammation, intra-alveolar edema, denuding
of large airways and cellular debris in large airways was readily ob-
served (Fig. 4e-h). Consistent with the dramatic gross hemorrhaging
observed at the 5 × 104 PFU and 5 × 105 PFU doses (Fig. 2c), red
blood cells were frequently detected in the large airways, and alveolar
spaces (Fig. 4c,f,h). Interestingly, despite the mild weight loss observed
at the 5 × 103 PFU dose (Fig. 2a), mice exhibited respiratory pathology
consistent with respiratory disease including intra-alveolar edema,
perivascular cuffing, and severe inflammation (Fig. 4i-k and Table 1),
although many areas displayed normal lung morphology (Fig. 4l). Our
results indicate that maM35c4 elicited dose-dependent pathological
changes, primarily hyaline membrane formation, in the lower re-
spiratory tract that reflect a loss of respiratory function, and are com-
mensurate with weight loss, increased mortality, and increased he-
morrhaging in the lungs of infected 288–330+/+ mice. Achieving
dramatic disease at 5 × 105 and 5 × 104, and to a lesser extent at 5 ×
103 PFU, demonstrates that severe respiratory disease was comparable
to that seen at 5 × 106 PFU for icMERSma1, and suggests that
maM35c4 acquired additional mutations that enhanced virulence.
2.4. Identification of MERS-CoV- mutations acquired during adaptation
Sequencing the genome of the plaque purified maM35c4 revealed
several unique mutations acquired during serial passaging, including a
single nucleotide change in the 5′ UTR and single amino acid changes in
nonstructural proteins nsp3, nsp6, nsp8 and nsp14 (Table 2). Novel
single amino acid changes were also observed in the spike protein, orf3,
orf4a, and membrane proteins (Table 2). Additionally, maM35c4 ac-
quired a large deletion extending from orf4b through the beginning of
orf5 (Table 2). Though unique, mutations in 5′ UTR, nsp6, nsp8, spike
protein, and Orf4b were also present in the previously adapted ic-
MERSma1 virus (Cockrell et al., 2016). Most notable are the mutations
that remained after the additional 20 rounds of adaption to achieve the
maM35c4 virus, nsp8 (I108L), spike insertion of RMR, and spike mu-
tation of S885L [Table 2 and (Cockrell et al., 2016)], implicating these
mutations as critical for eliciting respiratory disease in our mouse
model. Although maM35c4 mutations in the 5′UTR and nsp6 are dif-
ferent from those in the icMERSma1 virus, acquiring novel mutations in
the same viral genetic domains implicates the 5′UTR and nsp6 as im-
portant regions for MERS-CoV to elicit respiratory disease in our
288–330+/+ mouse model. In contrast, mutations acquired in orf3,
orf4b, and orf5 indicate that their function is expendable for maM35c4
to elicit respiratory disease. Importantly, the N222Y spike mutation is
notably similar to an N222D mutation that was acquired by a mouse-
adapted MERS-CoV described in a recent study (Li et al., 2017a). Our
sequencing results demonstrate that the spike mutations are all highly
conserved mouse-adaptations between strains from our lab (Insertion
RMR and S885L), as well as strains between labs [N222Y for ma-
MERS35c4 and N222D from (Li et al., 2017a)]. The conserved nature of
these mouse-adapted mutations prompted us to investigate their po-
tential in altering structuring features of the MERS-CoV spike using
structural prediction software to place these mutations in the context of
the spike trimer.
2.5. Structural comparison of maM35c4 spike mutations
Homology based structural modeling was used to understand how
the conserved mouse-adapted spike mutations may influence the
structure of the MERS-CoV trimers when placed on the prefusion spike
trimer determined by Yuan et al. (2017) using cryo-EM . The maM35c4
spike mutations identified in this study and MA2.0 mutations identified
by Li et al. (2017a) were compared to the S1 and S2 domains of spike
from EMC 2012 (Fig. 5a). Each of the spike mutations indicated in
Fig. 5a, and Table 1, was placed onto each monomer of the MERS-CoV
spike trimer (Fig. 5b). Using the freely available prediction software
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Fig. 3. Immunohistochemistry reveals high levels of maM35c4 infection in 288–330+/+ mouse lungs. Mouse lung sections were stained for MERS-CoV nucleocapsid antigen to
identify lung cells positive for maM35c4 infection. Representative images are shown for lung sections from mice infected with doses of 5 × 105 (a,d), 5 × 104 (b,e), or 5 × 103 (c,f) PFU
at 3 days and 7 days p.i. All images were acquired at 40X magnification. Images are representative of at least 3 samples. Scale bars in lower right corners of each panel are 1 mm.
glycosylation site. Though the N222Y mutation occurred at the same
position as the N222D mutation in the N-terminal domain, replacing
the polar amino acid N with a nonpolar, uncharged Y residue appears to
result in a slight structural modification; whereas, the N222 structural
feature appears to be maintained in the context of the negatively
charged D residue (Fig. 5b,d). Also highlighted on the trimer spike
structures are the RMR insertion and the S885L spike mutations in the
S2 domain (Fig. 5b), which were conserved across the maM35c4 and
icMERSma1 strains. Interestingly, the maM35c4 RMRL mutations (red)
directly overlap with part of the S2′ fusion domain (yellow), and ap-
parently alters the S2′ furin cleavage site (Millet and Whittaker, 2014)
(Fig. 5c, green). Using freely available furin cleavage site prediction
software (ProP 1.0 Server) we determined that insertion of RMR most
likely generated a novel furin cleavage site. The mouse-adapted muta-
tions in spike may have important implications regarding enhancing
viral replication and determining tropism, but ARDS-like respiratory
disease is most likely dependent on the combination of spike mutations
and conserved mutations that we have identified at other MERS-CoV
genetic loci.
3. Discussion
3.1. Adaptive evolution influences MERS-CoV virulence
This study found that extending the passage of MERS-CoV through
288–330+/- mice enhanced virulence, achieving severe respiratory
disease at 10–1000 fold lower doses than those seen with earlier pas-
sage 15 viruses (Cockrell et al., 2016). Continued adaptive evolution for
an additional 20 rounds generated maM35c4, which is capable of eli-
citing comparable levels of disease at significantly lower doses (103 –
105 PFU). The ability to use lower challenge doses more likely reflects
MERS-CoV infection in humans. Nosocomial transmissions have been
the primary source of outbreaks [reviewed in (Arabi et al., 2017)].
Importantly, individuals that are older (> 50), and/or those that have
co-morbidities (e.g. diabetes, hypertension, etc.) are at higher risk of
severe disease. Therefore, individuals presenting with pre-existing
conditions may be more susceptible to disease at lower viral doses. A
recent study demonstrated that the patient room environment (e.g. bed
sheets, bed rails, IV fluid hangers, radiography cassettes and anteroom
tables) in the healthcare setting was readily contaminated with re-
plication competent MERS-CoV (Bin et al., 2016). MERS-CoV was de-
tected on numerous additional surfaces by RT-PCR, indicating con-
tamination throughout patient rooms (Bin et al., 2016). Although it is
not clear what dose of virus is necessary to establish infection and
disease in humans, it is not unlikely that low dose contaminated en-
vironmental sources contributes to hospital transmission. Thus, evalu-
ating a broad range of dosing options (103–107) in our mouse model
affords us the unique ability to investigate at least three independent
lines of research: i) how varying infectious dose influences MERS-CoV
pathogenesis; ii) therapeutic efficacy at different infectious doses; and
iii) comparative genetics of different mouse-adapted strains to in-
vestigate MERS-CoV genetic correlates of respiratory disease.
Comparative genetics of the mouse-adapted icMERSma1 virus (15
passages) with maM35c4 (35 passages) provides insight into how
adaptive evolution augments virulence of MERS-CoV in a mouse model.
In addition to a number of novel mutations we identified specific mu-
tations in the maM35c4 virus that remain conserved through an addi-
tional 20 passage, and may be instrumental for conferring severe re-
spiratory disease in mice. Furthermore, we identified a missense
mutation site in the spike protein that was independently identified in a
different model of adaptive evolution (Li et al., 2017a), implicating this
site as central to enhanced MERS-CoV pathogenesis in the mouse. We
also observed mutations in multiple nonstructural proteins, structural
proteins, and several orf's that may influence MERS-CoV pathogenesis




































































































































































































































































































































































































































































































































































































































































































































































3.2. Mouse-adapted M35c4 nonstructural protein mutations
The orf1a/1b genomic regions are conserved throughout the
Coronaviridae family and encode 16 nonstructural proteins (nsp's) that
compose the replication and transcription complex. Mouse-adapted
M35c4 acquired unique mutations in several non-structural proteins
including nsp3, nsp6, nsp8 and nsp14, including novel missense mu-
tations in nsp3, nsp6, and nsp14 as compared to icMERSma1. Curiously,
the mutation in nsp8 (I108L) remained fixed following an additional 20
rounds of adaptive evolution. An isoleucine to leucine mutations could
be considered a minor exchange of two hydrophobic residues that may
have little impact on nsp8 functions in fidelity and processivity, espe-
cially considering that a hydrophobic residue at this position is con-
served across many coronaviruses [see alignment in (Subissi et al.,
2014)]. The nsp8 from severe acute respiratory syndrome coronavirus
(SARS-CoV) was demonstrated to form a tripartite complex with nsp7
and nsp12, and confer processivity to the RNA synthesizing activity of
nsp12 (Subissi et al., 2014). The nsp8/nsp12 interaction was found to
be critical for RNA-dependent RNA polymerase activity of nsp12
(Subissi et al., 2014). At this time, it is not clear whether the I108L
mutation impacts virus processivity or alters pathogenesis of MERS-CoV
by some other mechanism. For example, Subissi et al. also demonstrate
that the nsp7/nsp8/nsp12 tripartite complex associates with nsp14 to
augment the fidelity of viral replication by commandeering the proof-
reading mechanism of the exoribonuclease and the N7-methyl-
transferase activities (N7-MTase) (Subissi et al., 2014). In addition, we
identified a missense mutation (T521I) in the N7-methyltransferase
domain of nsp14. A number of studies have investigated the impact of
mutations across nsp14 on coronavirus replication [reviewed in




Fig. 4. Mouse-adapted M35c4 elicits pathology associated with ARDS. Representative images were acquired from mouse lungs infected with maM35c4 at doses of 5 × 105 (a-d), 5 ×
104 (e-h), or 5 × 103 (i-l) PFU at day 7 p.i. Images reflect the severity of disease observed at the different doses including denuding of large airways (a, d, h), debris in the airways (a, d, f,
h), hyaline membranes (a-e), red blood cells in the large airways and alveoli (c, f, h), edema (c, d, g, I, k), and perivascular cuffing (j). A normal region of a mouse lung at the 5 × 103 PFU
dose is shown (l). Image (a) was captured at 10X magnification and all other images were acquired at 40X magnification. Images are representative of at least 3 samples. Scale bars in
lower right corners of each panel are 1 mm.
Table 2
maM35c4 mutations.
MERS region/protein Type of mutation in maM35c4 clone Amino acid position Nucleotide change Nucleotide numbering
5′ UTR single nucleotide change N/A CTCACTT → CTCGCTT 28
nsp3 Missense A217V GCA → GTA 3486–3488
nsp3 Missense T1615N ACT → AAT 7680–7682
nsp6 Missense L232F CTT → TTT 11631–11633
nsp8a Missense I108L ATT → CTT 12384–12386
nsp14 Missense T521I ACA → ATA 19562–19564
spike Missense N222Y AAT → TAT 22119–22121
spikea Insertion of RMR R884-RMR-S885L AATGCGGCT 24109||24110
spikea Missense S885L (L is 888 in new sequence) AGT → CTT 24108–24110
Orf3 Nonsense Q4stop CAA → TAA 25541–25543
Orf4a Missense P85L CCT → CTT 26104–26106
Orf4b/Orf5 Large deletion between Orf4b & Orf5 N/A GATTTT…Δ…AAACCC 26211–26863
Membrane Missense S2F TCT → TTT 27856–27858
Protein and nucleotide sequence numbering is based on the EMC 2012 sequence (JX869059.2) with nonstructural protein annotations described in NC_019843
Numbering for the amino acids begins with the first amino acid of each individual protein.
a Mutations that can also be found in icMERSma1 (Cockrell et al., 2016).
nsp8 and nsp14 influence MERS-CoV pathogenesis, future studies are
warranted to investigate the role of these changes in disease.
Although the missense mutation in nsp6 (L232F) of maM35c4 was
novel in this study, a different mutation in nsp6 was identified in the
icMERSma1 virus (T184I) (Cockrell et al., 2016), implicating nsp6 as an
important MERS-CoV genetic locus for acquiring mutations during
adaptive evolution in mice. The nsp6 protein from SARS-CoV has been
demonstrated to be involved in the formation of double-membrane
vesicles (DMVs) that anchor membrane-bound replication complexes
(Angelini et al., 2013). Lundin et al. recently demonstrated that an
inhibitor, K22, selectively targets DMVs formation in HCoV-229E in-
fected cells and selects for resistance mutations in nsp6 (Lundin et al.,
2014). As K22 also inhibits MERS-CoV replication in vitro (Lundin et al.,
2014), nsp6 mutations might enhance virus replication and pathogen-
esis in vivo and requires additional study. Evaluating the effect of K22
on the mouse-adapted nsp6 mutations, compared to wild-type nsp6,
will be the subject of future in vitro and in vivo studies.
Mouse-adapted M35c4 revealed two novel missense mutations in
nsp3 (A217V and T1615N). The nsp3 protein is a multi-domain protein
with multiple functions as indicated for SARS-CoV (Baez-Santos et al.,
2015). Using the SARS-CoV model as a guide, the A217V mutation
likely resides in the catalytically active ADP-ribose-1″-phosphatase
domain (ADRP domain, a.k.a. macro domain or X domain) (Baez-Santos
et al., 2015), and the T1615N mutation would reside in the Y domain
toward the carboxy terminus of nsp3 (Baez-Santos et al., 2015). These
domains remain largely uncharacterized, with the exception of the
crystal structure of the ADRP domain being solved for SARS-CoV, and in
vitro assays confirming the nsp3 phosphatase activity (Egloff et al.,
2006; Saikatendu et al., 2005). Moreover, mutations in the catalytic
domain of ADRP alter pathogenesis, but not replication, suggesting that
these mutations may play important roles in virus-host interactions and
disease (Fehr et al., 2015).
Importantly, our data is further supported by the discovery of mu-
tations in nsp3, nsp6, and nsp14 that were independently identified in a
different mouse-adapted MERS-CoV (Li et al., 2017a). Independent
verification is strongly suggestive that mutations in these nsps play a
critical role in MERS-CoV pathogenesis and the development of severe
respiratory disease. Clearly, panels of recombinant viruses will be
needed to unravel the role of each of the nsp mutations in virus re-
plication and pathogenesis in vivo.
3.3. Mouse-adapted M35c4 conserved spike mutations
As the primary determinant of MERS-CoV tropism, changes in the
spike protein are of particular interest when evaluating mouse-adapted
coronaviruses. We noted that the spike protein of maM35c4 included a
missense mutation at a putative glycosylation site (N222Y). Similarly,
Li et al. also observed a mutation at the same position (N222D).
Structural predictions showed minor differences in the structural
modification between the two mutants (Fig. 5b,d). Although a change
from a nonpolar, uncharged tyrosine residue to a negatively charged,
aspartic acid residue, may have differing functional consequences, the
common theme between these independently acquired mutations is the
loss of a putative glycosylation site at this position. The N222 position
resides in the N-terminal domain of S1 and is structurally distinct from
the receptor binding domain (Fig. 5b), which is the major determinant
of viral tropism through interaction with DPP4 (Hulswit et al., 2016).
Recent studies have shown that the coronavirus S1 domain folds into 4
Fig. 5. Structural modeling of the maM35c4 spike mutations against EMC 2012 and MA2.0. a. Alignment of the amino acid sequences identified in the S1 and S2 domains from EMC
2012, maM35c4, and MA2.0. The colors in S1 correspond to amino acid sequence changes in the N-terminal domains (NTD) of maM35c4 (magenta, N222Y), and MA2.0 (blue, N222D)
compared to EMC 2012 (orange). In the S2 domain the RMR insertion and S885L mutations in maM35c4 (red) are compared to the wild-type sequence in EMC 2012 and MA2.0 (green).
The S2′ fusion domain region is highlighted in yellow. Varying shades of light gray to black in the S1 and S2 diagrams correspond with the same coloring scheme depicted for the spike
trimers in (b). b. Structural modeling of MERS-CoV monomers was conducted using the PHYRE2 online modeling software; trimers were constructed using the PyMOL Molecular Graphics
System. All the respective mutations identified within the spikes of maM35c4 and MA2.0 were incorporated into the modeled structure. The additional mutations in MA2.0 are not visible
on the surface of the structure as shown. c and d. Expanded views of the structural regions observed near the S2′ and fusion domains of EMC 2012 and maM35c4 (c) and the region of the
NTD encompassing amino acid N222 from EMC 2012, maM35c4, and MA2.0 (d).
et al., 2013). The N terminal regions from SARS-CoV and MERS-CoV M
proteins were shown to be sufficient to inhibit interferon expression
(Lui et al., 2016; Siu et al., 2014). In the case of MERS-CoV the N-
terminus of the M protein was found to interact with TRAF3 and disrupt
the TRAF3-TBK1 association that leads to IRF3 activation (Lui et al.,
2016). We identified a missense mutation (S2F) at the N-terminus of the
M protein. Li et al. (2017a) also identified a missense mutation at the N-
terminus of the M protein in their mouse-adapted MERS-CoV. Missense
mutations at the N-terminus of SARS-CoV M protein have also been
associated with increased pathogenesis in mice (Roberts et al., 2007),
and enhanced virus production following adaptation in tissue culture
(Pacciarini et al., 2008). Taken together, these studies imply that MERS-
CoV and SARS-CoV may share conserved functions that reside in the M
protein N-terminus that may contribute to pathogenesis in mice.
4. Conclusion
We have developed a robust mouse model for MERS-CoV patho-
genesis that recapitulates lethal end stage lung phenotypes after low
dose challenge. In addition to achieving a low challenge dose, con-
tinued adaptive evolution identified conserved, and novel mutations,
throughout the MERS-CoV genome that may have functional implica-
tions regarding the phenotypes observed during infection. Future stu-
dies will include the generation of a MERS-CoV infectious clone con-
taining all the mutations to confirm the observed disease phenotypes at
the infectious doses described in this study; and, the subsequent gen-
eration of novel viruses with different combinations of mutations to
evaluate their role in replication and severe respiratory disease. As
disease pathology replicates many of the end stage lung disease phe-
notypes seen in humans, this model will be valuable for evaluating
pathogenic mechanisms of MERS-CoV, host immune responses to
MERS-CoV, and the use of therapeutics and vaccines to reverse disease
signatures.
5. Materials and methods
Unless otherwise indicated details for each of the following head-
ings can be found in (Cockrell et al., 2016)
5.1. Cells and viruses
Maintenance and preparation of cells and virus stocks can be found
in (Cockrell et al., 2016).
5.2. Mouse infections
All infections were done as previously described in 288–330+/- or
288–330+/+ mice (Cockrell et al., 2016). Briefly, since the 288–330+/
+ mice are novel mouse lines developed and bred in the Baric lab,
experiments utilized available male and female mice that ranged 18–22
weeks of age. Mice were randomly included into cohorts at the in-
dicated time points. Mouse studies were executed under ABSL3 condi-
tions. Prior to viral infection mice were anesthetized by administering
50ul of a ketamine/xylazine mixture intraperitoneally, and then in-
fected intranasally with a 50ul volume of virus at the indicated dose.
Following sedation and infection mice were monitored daily for weight
loss and survival, as well as signs that animals were moribund (in-
cluding labored breathing, lack of movement, and lack of grooming).
Mice that reached 20% weight loss were placed under exception, and
monitored at least three times daily. Mice that approached 30% weight
loss were immediately euthanized. Mice deemed moribund were eu-
thanized at the discretion of the researcher. Mice were euthanized with
an isoflurane overdose followed by a secondary thoracotomy, at the
time points indicated in the results, for collecting lung tissues. All
methods are approved methods of the Institutional Animal Care and
Use Committee (IACUC) at The University of North Carolina at Chapel
distinct subdomains referred to as S1A – S1D (Kirchdoerfer et al., 2016; 
Walls et al., 2016). The N222 mutation is positioned within the S1A 
subdomain, which was recently demonstrated to support a predominant 
interaction with host α2,3-linked sialic acid relative to interaction with 
α2,6-linked sialic acid (Li et al., 2017b). The distribution of host α2,3-
linked sialic acid residues in humans and camels correlates with MERS-
CoV infections in the lower and upper respiratory tract of each of the 
respective species (Li et al., 2017b; Widagdo et al., 2016). It was pro-
posed that the α2,3-linked sialic acid residues may facilitate an initial 
low affinity interaction with cells, prior to a high affinity interaction 
between the RBD in S1B and host DPP4 receptor (Li et al., 2017b). 
Elimination of the putative N222 glycosylation site through adaptive 
evolution in the mouse may influence the initial interaction with sialic 
acid residues, possibly enhancing infection or expanding host cell 
tropism.
The S1 domain is proteolytically separated from the S2 domain by a 
furin cleavage at the S1/S2 interface (Millet and Whittaker, 2014). A 
second furin cleavage site is thought to be cleaved upon viral entry and 
is referred to as S2′ (Millet and Whittaker, 2014). Mouse-adapted 
M35c4 has an RMR insertion and S885L mutations in the S2 domain of 
the MERS spike. These mutations were originally acquired from pas-
saging on murine NIH 3T3 cells in tissue culture (Cockrell et al., 2016) 
and remained fixed through all 35 rounds of adaptive evolution in the 
mouse. Placing our mutations in the context of the MERS-CoV spike 
trimer demonstrated that these mutations disrupt the canonical S2′
cleavage site in EMC 2012. Nonetheless, using cleavage site prediction 
software it appears that these mutations created a novel furin re-
cognition site. We previously demonstrated that a MERS-CoV strain 
harboring only these mutations (MERS-0), can replicate with faster 
kinetics in tissue culture and to higher titers than EMC 2012 in mouse 
lungs (Cockrell et al., 2016). We suspect that the novel furin cleavage 
site is more amenable to processing by mouse furin and thereby can 
enhance the kinetics of viral replication, but this remains to be tested. 
Importantly, the mutations in S2 alone were not sufficient to elicit re-
spiratory disease, even at high (5 × 106 PFU) viral doses (Cockrell 
et al., 2016). Therefore, a combination of mouse-adapted mutations 
may be necessary to elicit severe respiratory disease.
3.4. Mouse-adapted M35c4 mutations in accessory ORFs and the M protein
A number of studies have implicated the MERS-CoV accessory ORFs 
(ORF4a, ORF4b, ORF5) and M protein as potential antagonists of the 
innate immune response (Matthews et al., 2014; Menachery et al., 
2017; Rabouw et al., 2016; Thornbrough et al., 2016; Yang et al., 2015, 
2013). We identified a large deletions in ORF4b that extended through 
the beginning of ORF5, essentially eliminating expression of these 
proteins. Li et al. also identified a large deletion in ORF5, as well as a 
number of other ORF deletions, in their mouse-adapted viruses (Li 
et al., 2017a). Expression of ORF3 from maM35c4 was also eliminated 
since a nonsense mutation (Q4stop) was identified at the 5′ end of the 
protein. Additionally, we identified a missense mutation (P85L) in 
ORF4a, which is outside putative RNA binding domains. Considering all 
the accessory ORFs, only ORF4a appears to be expressed from 
maM35c4. ORF3, much of ORF4b and ORF5 appear to be dispensable 
for MERS-CoV pathogenesis in mouse lungs. Nonetheless, Menachery 
et al. demonstrate that using an infectious clone of the icMERSma1 
virus with complete deletion of ORFs 3–5 resulted in attenuation in 
mice (Menachery et al., 2017). If we combine this observation with data 
from our current maM35c4 isolate we can speculate that ORF4a may 
act as a strong interferon antagonist in mice to facilitate development of 
severe respiratory disease. Interestingly, MERS-CoV isolates have also 
been obtained from human patients with deletions in ORF3 and ORF4a; 
albeit, only 16 amino acids were deleted from ORF4a (Lamers et al., 
2016).
In vitro studies have also demonstrated that the MERS-CoV M pro-
tein may function as an interferon antagonist (Lui et al., 2016; Yang
software including the MPI Bioinformatics toolkit and the SWISS-
MODEL server from the SIB Bioinformatics Resource Portal. Due to
redundancy in the models only the model based upon the PHYRE 2
software is included in the manuscript.
5.8. Biosafety and biosecurity
A detailed description is available in Cockrell et al. (2016). Re-
garding continuation of gain-of-function experiments. In vivo adapta-
tion is in accordance with our US NIH award HHSN272201000019I-
HHSN27200003 (R.S.B.). Work for this study is agreement with receipt
of our exemption from the US Government's statement on funding
pause for certain types of GOF research.
5.9. Data availability
The data that support the findings of this study are available from
the corresponding authors on request
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